Slides
Page 1
25 February 2026 FY 2025 results
Page 2
Disclaimer This presentation contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law. This presentation includes non-IFRS financial measures as defined by Sandoz. An explanation of non-IFRS measures can be found in the Supplementary financial information of the Integrated Annual Report 2025. Certain figures contained in this presentation, including financial information presented in billions or millions, certain operating data and percentages describing financial information or market shares, have been subject to rounding. Dollar values and percentages may not agree to totals. JP Morgan Healthcare Conference
Page 3
Agenda 9M 2025 sales update 1. Highlights and business update Richard Saynor, CEO Financials Remco Steenbergen, CFO Wrap-up Richard Saynor, CEO Questions Richard Saynor, CEO | Remco Steenbergen, CFO 2. 3. 4. 3
Page 4
Highlights and business update Richard Saynor Chief Executive Officer
Page 5
A strong year of strategic and financial progress, cementing our fundamentals 5 1 USD 11.1 bn in net sales Core EBITDA margin +1.6% pts to 21.7% Management FCF of USD 1.5 bn (+ USD 0.4 bn) Core ROIC 14.5% (+2.2% pts) Dividend proposal of CHF 0.80 per share1 Financials FCF: free cash flow. 1. Subject to approval at Annual General Meeting on April 9, 2026. New Slovenia facilities to create European biosimilar hub and global market reach Acquisition of Just-Evotec Biologics EU SAS Leading vertically integrated platform to capture significant biosimilars growth opportunities Development and supply Strong launch execution: Wyost® & Jubbonti® (denosumab) Pyzchiva® (ustekinumab) Pyzchiva autoinjector Afqlir® (aflibercept) Tyruko® (natalizumab) Launches Industry-leading pipeline with 27 biosimilars Advancing in targeted and high-impact key biologics and therapies Significant expansion through business development and partnership Pipeline
Page 6
Strong underlying net-sales growth fuelled by launches Net-sales growth and mix CC: constant currencies. CGR: growth adjusted for 2024 acquisition of biosimilar Cimerli and 2024 divestment of China business, at CC. 6 in USD billions 0 10 28% 72% FY 2024 30% 70% FY 2025 10.4 11.1 5% at CC 6% at CGR Generics Biosimilars 0 4 28% 72% Q4 2024 31% 69% Q4 2025 2.7 3.0 6% at CC 7% at CGR 17 quarters of consecutive growth at CC 1
Page 7
>400 total assets in development, targeting USD ~220 bn1 of originator sales KEY LAUNCHES IN 2025 Generics: strong foundation for sustainable growth Scale, launches and pipeline providing stability and cash generation 7 1. Covers EU and US markets (2026–2035). Originator sales and LoEs based on internal analysis of data from multiple subscription databases. Generics data (oral solids, GLP-1, injectables, others) accessed in June 2025. LoE: loss of exclusivity. . . Iron sucrose Rivaroxaban Enoxaparin sodium Focused LoE coverage, centered on oral solids and injectables 4 development centers 15 in-house manufacturing locations Pipeline Portfolio strategy Sites 1
Page 8
Afqlir Launched in Europe in Q4 2025 US launch anticipated in Q4 20261 Delivering on biosimilars: strong launch execution 8 Pyzchiva autoinjector First commercially available autoinjector in Europe for ustekinumab biosimilars Tyruko Strong uptake in Europe, with more launches to come Launched in US in Q4 2025 Pyzchiva Launched in US in Q1 2025 Wyost & Jubbonti Launched in US in June 2025 First denosumab biosimilar in US 1. Or earlier, in certain circumstances. Wyost & Jubbonti Launched in Europe in Q4 2025 First denosumab biosimilar in Europe 1
Page 9
Pyzchiva European market share1 Pyzchiva: strong growth in Europe Hyrimoz: broadest payer coverage in US 1 Biosimilars participation growing in Europe; faster market adoption compared to adalimumab Strong launch of first biosimilar ustekinumab autoinjector in Europe Additional launches planned across Europe and International Sandoz market share Biosimilars participation Biosimilars participation (%) Sandoz market share (%) 1. Based on IQVIA MIDAS Sep 2025 update (volume in standard units); data for key 18 EU markets; market share among biosimilars. 2. Based on IQVIA Sep 2025 update (volume in standard units), Data for key 37 markets. Sandoz adalimumab includes Hyrimoz and adalimumab-adaz. Hyrimoz data exclude Cordavis private-label sales. Market share among biosimilars & originator. 9 0 25 50 Q4 2024 Q1 2025 Q2 2025 Q3 2025 40% 39% 36% 34% Biosimilars participation growing alongside stable global share Good European performance accompanied by exceptional growth in International markets US leadership position driven by private-label Hyrimoz and own- label adalimumab-adaz, with broadest payer coverage Hyrimoz global market share2 0 60 70 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 13% 12% 13% 13% 13% Sandoz market share Biosimilars participation 13% Biosimilars participation (%) Sandoz market share (%)
Page 10
Tyruko European market share1 Tyruko: encouraging progress and additional launches Omnitrope: stable and leading market share 1 First and only biosimilar approved in Europe and US for relapsing remitting multiple sclerosis Helping drive accessibility and affordability Additional launches planned across Europe and International Sandoz market share (%) 1. Based on local-market data (volume in grams) and determined by Sandoz launch countries, including originator in intravenous and subcutaneous markets. 2. Based on IQVIA MIDAS Sep 2025 update (volume in grams), including originator products (once-daily); excludes Mexico. 10 Market leader, with 36% global share2 International region driving growth, though increasing levels of competitor activity Omnitrope global market share2 Sandoz market share (%) 0 20 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 7% 15% 17% 18% 17% 18% 30 35 40 0 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q3 2025 28% 31% 31% 32% 35% 36% 35% 35% 35% 37% 36% Q2 2025
Page 11
Wyost & Jubbonti: successful launches 11 Strong access and uptake in US; first to market in Europe Established commercial footprint covering >80% of denosumab volume Established ASP in US Led with interchangeable- product exclusivity Broad provider access and early wins with key payers ASP: average sales price. 1 Europe launch progressing well thanks to strong leadership across both hospital and retail channels enabling superior field execution
Page 12
Industry-leading high-impact biosimilars pipeline Targeted development in key biologics and therapies 12 1. See appendix for current status reflecting regulatory streamlining. Third-party trademarks are property of their respective owners. The published biosimilar pipeline references significant commercial opportunities across a range of markets. Sandoz brand Originator brand Assets in technical development1 Assets in regulatory review / yet to launch Avzivi® (bevacizumab) Lantus® (glargine) NovoLog® (aspart) Herwenda® (trastuzumab) Humalog® (lispro) Assets in clinical development1 Ocrevus® (ocrelizumab SC) Darzalex® (daratumumab SC) Tecentriq® (atezolizumab) Skyrizi® (risankizumab) Tremfya® (guselkumab) Eylea HD® (aflibercept 8 mg) Dupixent® (dupilumab) Enhertu® (trastuzumab deruxtecan) Opdivo® (nivolumab IV) Keytruda® (pembrolizumab IV) Ocrevus® (ocrelizumab IV) Yervoy® (ipilimumab) Perjeta® (pertuzumab) Assets in early development Ultomiris® (ravulizumab) Reblozyl® (luspatercept) Opdivo Qvantig® (nivolumab SC) Takhzyro® (lanadelumab) Padcev® (enfortumab vedotin) Keytruda Qlex® (pembrolizumab SC) Tezspire® (tezepelumab) Vyvgart/Hytrulo® (efgartigimod alfa IV/SC) Vabsymo® (faricimab) 27 assets 1
Page 13
Purpose and impact highlights in 2025 Championing Sustainability Driving Access and Impact1 Empowering our People Governing with Integrity • Reaching over 1 billion patients in 100+ countries • ~USD 26 billion healthcare system savings delivered • ~USD 400 billion estimated social impact2 • Reduced carbon emissions3 by 5% at intensity level, with 2% absolute reduction • Submitted SBTi targets for validation across all emission scopes • Three Sandoz labs awarded My Green Lab® Certification in 2025; aim to certify 100% of Sandoz labs by 20274 • 40% of Board of Directors, 50% of Executive Committee, and 46% of management are women • Achieved a collective company rating of 4 from Glassdoor vs. the global pharmaceutical industry benchmark of 3.5 • Board oversight and risk-based controls for fast, practical decision-making without compromising assurance • 96% Code of Ethics and 95% Anti-Bribery training completion • Open, compliant Transfer of Value disclosures across 36+ markets 13 1 1. For details on methodology, please see Sandoz.com/ESG_supplementary_disclosures_2025. 2. Based on 2023 WifOR Institute analysis. 3. Scope 1, Scope 2 and Scope 3 emissions. 4. My Green Lab considered highest level of laboratory sustainability certification worldwide.
Page 14
Vertical integration in biosimilars: a key competitive advantage, creating best-in-class biosimilar capabilities 14 Capitalizing on biosimilar-market opportunity European biosimilar sites • European biosimilars leader • Top-tier in-house development & manufacturing Sites in network Sites under construction • Strategic proprietary platforms for integrated development • Indefinite licence to JEB´s continuous technology manufacturing Just-Evotec Biologics EU SAS (JEB) acquisition End-to-end European hub • Ljubljana: state-of-art technical development center • Lendava: high-tech drug substance production center • Brnik: state-of-art aseptic production center Sites under construction / in network 1
Page 15
Remco Steenbergen Chief Financial Officer Financials
Page 16
Management free cash flow of USD 1,547 million: strong core EBITDA and slightly reducing working-capital Core margin expansion of 1.6% pts to 21.7% Margin increase primarily driven by favorable sales mix, cost control and operating leverage Underlying growth of 6% at CGR Double-digit biosimilars growth All regions contributing Strong sales, with accelerated growth in core EBITDA, management free cash flow, core ROIC and core EPS 16 2 USD 3.64 Reduced net financial expenses and lower effective tax rate 1. At constant currencies. CGR: growth adjusted for 2024 acquisition of US biosimilar Cimerli (ranibizumab) and 2024 divestment of China business, at CC. FCF: free cash flow. Core ROIC improved to 14.5%, up from 12.3%, reflecting enhanced operating performance Net sales +5%1 Core EBITDA +14%1 Management FCF +USD 435 m Core ROIC +220 bps Core diluted EPS +33%1
Page 17
Net-sales performance driven by 13% biosimilars growth 17 2 FY 2025 net-sales regional mix FY 2025 net-sales business mix In USD billions 30% 70% Biosimilars +13% Generics +2% 11.1 bn +5% All growth shown at constant currencies. In USD billions 54% 24% 22% North America stable International +7% Europe +6% 11.1 bn +5%
Page 18
18 2 in USD billions 1.9 2.1 0.8 0.9 Q4 2024 Q4 2025 2.7 3.0 +6% at CC CGR +20% +2% +7% CC: constant currencies. CGR: growth adjusted for 2024 acquisition of US biosimilar Cimerli and 2024 divestment of China business, at CC. in USD billions 7.5 7.8 2.9 3.3 FY 2024 FY 2025 10.4 11.1 +5% at CC CGR +18% +2% +6% Biosimilars Strong Europe biosimilars growth, including Pyzchiva and Hyrimoz International: continued strong performances from Omnitrope and Hyrimoz Generics Europe growth reflected launches in 2024 and 2025 International performance supported by price increases North America: successful launch of paclitaxel in Q4 2024 Full-year dynamics Full year Q4 Double-digit growth for biosimilars driven by launches Net sales by business
Page 19
All three regions delivered underlying growth Net sales by region 19 2 in USD billions 0.7 0.7 0.7 0.8 1.4 1.6 Q4 2024 Q4 2025 2.7 3.0 +6% at CC CGR +6% +14% +2% +7% in USD billions 2.4 2.4 2.6 5.4 5.9 FY 2024 2.7 FY 2025 10.4 11.1 +5% at CC CGR +6% +9% +5% +6% Full-year dynamics CGR: growth adjusted for 2024 acquisition of US biosimilar Cimerli and 2024 divestment of China business, at CC. Europe Generics launches from 2024 and 2025, paired with exceptional biosimilars performance International Price accretion in generics. Strong Omnitrope and Hyrimoz performance North America Performance underpinned by strong biosimilars growth, including Wyost & Jubbonti launches Full year Q4
Page 20
Strong volume growth, with price erosion remaining at low single digits Net-sales growth 2 20 in USD billions Strong biosimilars volume uptake across all regions Price erosion of 3% remaining lower than historic levels Net-sales in H2 2025 impacted by lower penicillin B2B sales, driven by price dumping from Asian API suppliers FX tailwind of 2% reflects appreciation of EUR and CHF vs. USD driving positive net- sales impact CC: constant currencies. 10.4 0.8 FY 2024 Volume Price FX FY 2025 -0.3 11.1 0.2 +7% in USD +5% at CC +8% -3% +2%
Page 21
FY 2025 Change USD % Change CC % Net sales 11,086 7 5 Core gross profit 5,613 7 5 Core gross-profit margin 50.6% Core EBITDA 2,405 16 14 Core EBITDA margin 21.7% Core diluted EPS USD 3.64 34 33 Strong profitability driven by success in biosimilars, cost control and operating leverage 21 2 Summary core P&L in USD millions Stable core gross-profit margin Core SG&A expenses reduced as a proportion of net sales Enhanced core D&R investment to strengthen pipeline further Core diluted EPS increased by 33% at CC CC: constant currencies.
Page 22
Core EBITDA margin improvement reflected better mix, cost leverage while enhancing D&R investment 22 2 Favourable mix from strong biosimilars growth, demonstrating resilience against price pressure Focus on reducing core SG&A expenses as a proportion of net sales Supporting pipeline through enhanced D&R investment % of net sales Core EBITDA margin FY 2024 1.3% Mix -1.1% Price erosion 1.2% SG&A -0.4% D&R 0.6% FX & Other FY 2025 20.1% 21.7% +1.6% pts
Page 23
Record management free cash flow reflected strong improvement in core EBITDA 23 2 Disciplined inventory management driving working-capital improvement Capex includes ongoing investments in Slovenia One-off items includes separation, transformation and legal costs FY 2025 free cash flow in USD millions FY 2024 1,112 -1,014 98 WC: working capital. FCF: free cash flow. 227 Core EBITDA Inventory 26 Other-WC & operating items -391 Interest and taxes -720 Capex Management FCF1 -673 One-off items Reported FCF 2,405 1,547 874
Page 24
Further strengthening our balance sheet 24 2 Gross debt: reflecting bond issuances, partly offset by repayment of term loans FX impact on gross debtdue to stronger EUR and CHF vs. USD Liquidity increaseddue to increase in free cash flow Net debt to core EBITDA ratio of 1.5x (FY 2024: 1.6x) Net debt in USD billions Dec 2024 Dec 2025 FX adjusted Dec 2025 Reported Gross debt 4.5 4.7 5.3 Liquidity 1.2 1.6 1.8 Net debt 3.3 3.1 3.6
Page 25
25 Capex peaking in 2026 as biosimilar hub nears completion 2 Capex Manufacturing Building significant biosimilar drug-substance and fill-finish capacity Intangible Intangible investments mainly related to BD&L and IT, with increase driven by IT upgrades to drive efficiencies 0.5 0.7 0.2 0.1 0.1 0.1 0.1 2025 2026E 0.7 1.1 Manufacturing BD&L IT Others in USD billions 0.1
Page 26
26 One-off costs reducing Total of ~USD 0.7 bn over 2025-2026 confirmed 1. Excluding software-implementation-cost-accounting impacts. 2 2023 2024 2025 2026E 0.3 0.7 0.4 ~0.3 Manufacturing footprint Transformation Separation One-off costs declining1 Opex, 2023 – 2026, in USD billion One-time separation investments in IT, manufacturing and development capabilities Transformation simplifying organizational structure and creating a right-fit business Implementing new future-ready IT systems Software-implementation-cost accounting impacts ~USD 50 million in 2025; similar expectations for 2026
Page 27
Mid-to high-single-digit Full-year 2026 guidance 27 Net-sales growth % at constant currencies Net sales +2% pts Core EBITDA margin No material impact Price erosion of low to mid-single digit percentage Foreign-exchange impacts: based on spot rates1 Key assumption Expansion of around 100 basis pointsCore EBITDA margin % of net sales Note: no material contribution from any potential launch of generic semaglutide expected in 2026. Guidance excludes any impacts of unforeseen events or unconfirmed developments, including imposition of new tariffs emanating from US government. 1. Using spot rates as per end of January 2026 and assuming they prevail for rest of year. 2
Page 28
Mid-term outlook confirmed Sustained top-line momentum and margin expansion Increasing from 24% in 2024 and 27% in 20252 to 30-40% in mid-term 2026E1 CAGR: mid-term to 2028 Mid-single digit % Net-sales growth Core EBITDA margin Dividend policy % of net salesAt constant currencies % of core net income Mid-to high-single digit % 1. Per full-year guidance. 2. Subject to approval at Annual General Meeting on April 9, 2026. 28 2 24 to 26% 2025 2026E1 2028E 21.7% +~100bps
Page 29
Wrap-up Richard Saynor Chief Executive Officer
Page 30
Entering a golden decade of unprecedented potential 30 Leading biosimilars pipeline 1. Covers US and EU markets (2026–2035). Originator sales and LoE based on internal analysis of data from multiple subscription databases. Generics data accessed in June 2025; biosimilar data accessed in September 2025. 2. Indicates current assets in development, irrespective of launch dates. LoE: loss of exclusivity. REGULATORY STREAMLINING USD ~320 bn LoEs over next decade1 of originator sales1 27 assets of LoEs over next decade1in development, targeting USD ~200 bn representing 59% 2 3 Strong generics pipeline USD ~340 bn LoEs over next decade1 USD ~220 bn >400 assets in development, targeting of originator sales1 of LoEs over next decade1 representing 65% 2 Longer term: GLP-1s
Page 31
Building momentum into 2026 Leadership in affordable medicines 3131 3 Accelerate access Upcoming launch of Enzeevu® (aflibercept) in US; maximizing 2025 launches Flawless execution Continue executing strategy and priorities by strengthening capabilities and living pioneering culture every day Slovenia Completion of state-of-art development and drug substance sites: vertical integration Just-Evotec Expanding in-house biosimilar development and manufacturing capabilities Consolidating position as undisputed leader in the sector
Page 32
Questions Richard Saynor Chief Executive Officer Remco Steenbergen Chief Financial Officer
Page 33
Appendix
Page 34
Strong balance sheet and liquidity to support future growth 1. As of December 31, 2025 New USD 2.0 billion multi- currency revolving credit facility replacing initial and unutilized USD 1.25 billion facility (March 2025) Dual-tranche CHF 400 million and single-tranche EUR 500 million bonds issued; proceeds used to repay term loans (March 2025) Debt maturities extended to 2035 Credit ratings S&P: BBB Moody’s: Baa2 Leverage Net debt to core EBITDA ratio below 2.0x in mid term Total financial debt incl. current portion by maturity1 in USD millions 2026 2027 2028 2029 2030 2031 20332032 2034 2035 34 1,000 500
Page 35
35 2 8 Pre-2025 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 15 7 43 30 6 42 62 23 insulin glargine insulin aspart trastuzumab insulin lispro bevacizumab pertuzumab ipilimumab pembrolizumab IV nivolumab IV nivolumab SC daratumumab ocrelizumab IV ocrelizumab SC dupilumab guselkumab pembrolizumab SC1 atezolizumab aflibercept HD1 ravulizumab efgartigimod alpha faricimab lanadelumab Current LoE opportunity for Sandoz pipeline assets 8 5 54 48 11 53 22 70 20 33 13 53 49 Overall LoE market value (USD bn) Sandoz pipeline assets LoE market value (USD bn) Note: Biologics with LoE-1 yr sales <USD 1 bn are excluded from analysis; LoE year (pre -2025, 2025 to 2036) based on Sandoz 27 molecul es. US or Europe LoE, whichever comes first. For development stage and disease indication, please refer to the appendix. 1. Refers to expected launch year, due to development timing, unrelated to LoE. Source: Originator sales and LoE based on internal analysis of data from multiple subscription databases (accessed September 2025). LoE: loss of exclusivity. risankizumab trastuzumab deruxtecan enfortumab vedotin luspatercept tezepelumab
Page 36
Global biosimilars pipeline (1/4) Key near-term launches and assets in regulatory review / yet to launch 36 Own/targeted brand Originator net sales targeted (USD bn)1 In-house/ partnered Current status LoE1 Herwenda® trastuzumab 2 Partnered Regulatory approval in Europe Regulatory submission in US EU: expired US: expired Avzivi® bevacizumab 2 Partnered Regulatory approval in Europe Regulatory approval in US EU: expired US: expired Lantus® glargine 4 Partnered Approved in Europe Regulatory submission in US EU: expired US: expired NovoLog® aspart 2 Partnered Regulatory submission in Europe Regulatory submission in US EU: expired US: expired Humalog® lispro 2 Partnered Regulatory submission in Europe Regulatory submission in US EU: expired US: expired Oncology Diabetes Note: third-party trademarks are property of their respective owners. 1. Originator sales (LoE-1) and LoE dates based on internal analysis from multiple subscription databases. LoE: loss of exclusivity.
Page 37
Global biosimilars pipeline (2/4) Assets in clinical development 37 Own/targeted brand Originator net sales targeted (USD bn)1 In-house/ partnered Current status LoE1 Keytruda® pembrolizumab IV 31 In-house In clinical development2 EU: 2031 US: 2028 Opdivo® nivolumab IV 10 In-house In clinical development2 EU: 2030 US: 2028 Perjeta® Pertuzumab 4 Partnered In clinical development2 EU: 2025 US: 2026 Yervoy® ipilimumab 3 Partnered In clinical development EU: 2026 US: 2025 Tecentriq® atezolizumab 4 In-house In clinical development3 EU: 2033 US: 2030 Ocrevus® ocrelizumab IV 5 In-house In clinical development3 EU: 2029 US: 2029 Oncology Neurology Note: third-party trademarks are property of their respective owners. 1. Originator sales (LoE-1) and LoE dates based on internal analysis from multiple subscription databases. 2. Winding down Phase III trial. 3. Modifying integrated Phase I and III trial to become a comparative pharmacokinetic trial. LoE: loss of exclusivity.
Page 38
Global biosimilars pipeline (3/4) Assets in technical development 38 Targeted brand Originator net sales targeted (USD bn)1 In-house / partnered LoE1 Darzalex® daratumumab SC 17 In-house EU: 2031 US: 2029 Enhertu® trastuzumab deruxtecan 15 In-house EU: 2036 US: 2033 Skyrizi® risankizumab 25 In-house EU: 2034 US: 2033 Tremfya® guselkumab 7 In-house EU: 2032 US: 2031 Eylea HD® aflibercept 8 mg 4 In-house EU: expired US: expired Ocrevus® ocrelizumab SC 4 In-house EU: 2029 US: 2029 Dupixent® dupilumab 24 In-house EU: 2033 US: 2031 Oncology Immunology Ophthalmology Neurology Dermatology Note: third-party trademarks are property of their respective owners. 1. Originator sales (LoE-1) and LoE dates based on internal analysis from multiple subscription databases. LoE: loss of exclusivity.
Page 39
Global biosimilars pipeline (4/4) Assets in early development 39 Targeted brand Originator net sales targeted (USD bn)1 In-house / partnered LoE1 Keytruda Qlex® pembrolizumab SC 8 In-house EU: 2031 US: 2028 Padcev® enfortumab vedotin 7 In-house EU: 2036 US: 2033 Opdivo Qvantig® nivolumab SC 2 In-house EU: 2030 US: 2028 Takhzyro® lanadelumab 2 In-house EU: 2033 US: 2032 Vyvgart®/Vyvgart Hytrulo® efgartigimod alfa IV / SC 12 In-house EU: 2037 US: 2036 Ultomiris® ravulizumab 8 In-house EU: 2035 US: 2035 Vabysmo® faricimab 11 In-house EU: 2037 US: 2036 Reblozyl® luspatercept 4 In-house EU: 2034 US: 2033 Tezspire® tezepelumab 5 In-house EU: 2033 US: 2034 Oncology Immunology Ophthalmology Hematology Respiratory Note: third-party trademarks are property of their respective owners. 1. Originator sales (LoE-1) and LoE dates based on internal analysis from multiple subscription databases. LoE: loss of exclusivity.
Page 40
Upcoming investor events 40 Sandoz EU and NA roadshow Paris, Zurich, Toronto, Boston, New York March 3-5, 2026 Barclays Global Healthcare Conference Miami March 10-11, 2026 Bank of America Pharma Bus Tour Basel March 12, 2026 Sandoz Annual General Meeting Basel April 9, 2026 Sandoz Q1 2026 sales update Virtual April 29, 2026 BNP Paribas Healthcare Conference London March 24, 2026 Jefferies Pan-Euro Mid-cap Conference London March 25, 2026 UBS European Healthcare Conference London March 3, 2026
Page 41
Investor Relations contacts 41 Tamara Hackl Silvia Siegfried Senior Director, IR Senior Director, IR Craig Marks Head of IR +44 7818 942 383 +41 79 790 52 17 +41 79 795 90 61 Katie Fischer Coordinator, IR +41 79 500 51 53 investor.relations@sandoz.com
Page 42
Thank you